Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118075 | 0.82 | ALDH1A1 (0.55) | PTGS1PTGS2GPBAR1LMNAALDH1A1 | |
| SCHEMBL10394013 | 0.80 | PTGS1 (0.66) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL10083918 | 0.80 | PTGS1 (0.66) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL14258658 | 0.77 | PTGS1 (0.62) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL8931495 | 0.76 | PTGS2 (0.59) | PTGS1PTGS2LMNAATMMAPT | |
| SCHEMBL13990626 | 0.76 | LMNA (0.53) | GPBAR1LMNAATMALDH1A1MAPT | |
| SCHEMBL256686 | 0.74 | PTGS1 (0.59) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL21119516 | 0.74 | PTGS1 (0.59) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL9967686 | 0.74 | ATM (0.61) | PTGS1PTGS2HSD17B10GPBAR1LMNA | |
| SCHEMBL2281131 | 0.74 | PTGS1 (1.00) | PTGS1PTGS2HSD17B10GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8552203-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552203-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8541618-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541618-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER HEALTHCARE LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | PTGS1 1005/4885PTGS2 1588/4885HSD17B10 1632/4885 |
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | ACHE, CHAT, APP | PTGS1 642/4885PTGS2 448/4885HSD17B10 265/4885 |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, AANAT | PTGS1 705/4885PTGS2 559/4885HSD17B10 250/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PTGS1 1041/4885PTGS2 990/4885HSD17B10 61/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PTGS1 887/4885PTGS2 730/4885HSD17B10 436/4885 |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | APP, MAPT, TNF | PTGS1 482/4885PTGS2 353/4885HSD17B10 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.